- Home
- MNOV vs AVTX Comparison
MNOV vs AVTX Comparison
Compare MNOV & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNOV
- AVTX
- Stock Information
- Founded
- MNOV 2000
- AVTX 2011
- Country
- MNOV United States
- AVTX United States
- Employees
- MNOV N/A
- AVTX N/A
- Industry
- MNOV Biotechnology: Pharmaceutical Preparations
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- MNOV Health Care
- AVTX Health Care
- Exchange
- MNOV Nasdaq
- AVTX Nasdaq
- Market Cap
- MNOV 76.0M
- AVTX 248.3M
- IPO Year
- MNOV 2005
- AVTX 2015
- Fundamental
- Price
- MNOV $1.47
- AVTX $18.51
- Analyst Decision
- MNOV Strong Buy
- AVTX Strong Buy
- Analyst Count
- MNOV 2
- AVTX 9
- Target Price
- MNOV $7.00
- AVTX $30.14
- AVG Volume (30 Days)
- MNOV 3.0M
- AVTX 356.6K
- Earning Date
- MNOV 11-12-2025
- AVTX 11-06-2025
- Dividend Yield
- MNOV N/A
- AVTX N/A
- EPS Growth
- MNOV N/A
- AVTX N/A
- EPS
- MNOV N/A
- AVTX N/A
- Revenue
- MNOV $257,917.00
- AVTX $192,000.00
- Revenue This Year
- MNOV N/A
- AVTX N/A
- Revenue Next Year
- MNOV N/A
- AVTX N/A
- P/E Ratio
- MNOV N/A
- AVTX N/A
- Revenue Growth
- MNOV N/A
- AVTX N/A
- 52 Week Low
- MNOV $1.13
- AVTX $3.39
- 52 Week High
- MNOV $2.48
- AVTX $19.41
- Technical
- Relative Strength Index (RSI)
- MNOV 53.16
- AVTX 63.55
- Support Level
- MNOV $1.40
- AVTX $16.75
- Resistance Level
- MNOV $1.63
- AVTX $19.29
- Average True Range (ATR)
- MNOV 0.08
- AVTX 1.34
- MACD
- MNOV -0.01
- AVTX 0.15
- Stochastic Oscillator
- MNOV 26.13
- AVTX 86.17
About MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's strategies are to focus its developing activities on therapeutics for neurological disorders and fibrotic diseases.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).